Givaudan
This article was originally published in The Rose Sheet
Executive Summary
First quarter fragrance sales decline 1.8% in Swiss Francs, or .3% in local currencies to $214.5 mil. (1 CHF=$0.77) due to discontinued sales of commodity ingredients, firm reports. Fine fragrances, however, experienced double-digit growth in local currencies driven by the launches of several prestige fragrances. Total sales in the quarter grew 2.4% in Swiss Francs, or 4.1% in local currencies, to $540.5 mil. Givaudan will continue to focus on developing proprietary fragrance ingredients this year, the company said during its annual investor meeting April 8. Among the exclusive ingredients Givaudan plans to launch is Toscanol, a replacement for Estragole, which has been found to be a naturally occurring genotoxic carcinogen. The company also will introduce Javanol, a sandalwood odorant at the World Perfumery Congress June 1-5 in Cannes, France, according to Givaudan Head of Fragrance Chemistry Markus Gautschi...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.